Robert Neil Hunter, Iii

USPTO Granted Patents = 7 (Patent Applications = 2)

Average Co-Inventor Count = 6.0

ph-index = 6

Forward Citations = 240(Granted Patents)

Location History:

Raleigh, NC (US) (2001 - 2006)
Durham, NC (US) (2007 - 2008)

Company Filing History:

5 out of 2,198

Smithkline Beecham Corporation

Years Active: 2001-2008

Loading Chart...

7 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 7329678 - Chemical compounds (2008-02-12),

2. 7189712 - 1,3-Oxazole compounds for the treatment of cancer (2007-03-13),

3. 7105529 - Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects (2006-09-12),

4. 6541503 - Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors (2003-04-01),

5. 6387919 - Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors (2002-05-14),

6. 6369086 - Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors (2002-04-09),

7. 6268391 - Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases (2001-07-31),

Title: Insights into the Innovations of Robert Neil Hunter, III

Introduction: Robert Neil Hunter, III, based in Durham, NC, has made significant contributions to the field of pharmaceuticals through his inventive prowess. With seven patents to his name, he is recognized for developing novel chemical compounds that offer potential treatments for various diseases.

Latest Patents: Among his latest inventions are the benzimidazolyl-pyridine derivatives, which serve as SGK-1 inhibitors. This patent outlines not only the chemical compounds but also the methods for synthesizing these compounds, providing therapeutic applications for diseases linked to inappropriate SGK-1 activity. Additionally, he has authored patents involving 1,3-oxazole compounds aimed at treating cancer, specifically functioning as inhibitors for VEGFR2, CDK2, and CDK4. This invention also highlights methods for producing these oxazole derivatives and their applications in managing hyperproliferative diseases.

Career Highlights: Robert has garnered experience through his tenure at prominent pharmaceutical companies. He has worked at SmithKline Beecham Corporation and Glaxo Wellcome Inc., where his expertise in chemistry and invention allowed him to contribute to the development of groundbreaking medications.

Collaborations: During his career, Robert has had the opportunity to collaborate with esteemed colleagues Scott Howard Dickerson and Philip Anthony Harris. These collaborations have helped to further advance his research and patent endeavors.

Conclusion: Robert Neil Hunter, III stands out as an innovative inventor within the pharmaceutical industry. His extensive patent portfolio and collaborative efforts have played a crucial role in the ongoing quest for effective treatments for complex medical conditions. His work continues to inspire future innovations in the field.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

2 patents pending:

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.